Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults

被引:32
作者
Chiu, Ming-Jang [1 ,2 ,3 ,4 ]
Fan, Ling-Yun [2 ,5 ]
Chen, Ta-Fu [1 ]
Chen, Ya-Fang [6 ]
Chieh, Jen-Jei [7 ]
Horng, Herng-Er [7 ]
机构
[1] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Neurol, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ, Grad Inst Brain & Mind Sci, Coll Med, Taipei, Taiwan
[3] Natl Taiwan Univ, Dept Psychol, Taipei, Taiwan
[4] Natl Taiwan Univ, Grad Inst Biomed Engn & Bioinformat, Taipei, Taiwan
[5] Taipei City Hosp, Neurol Sect, Dept Psychosomat Med, Taipei, Taiwan
[6] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Med Imaging, Coll Med, Taipei, Taiwan
[7] Natl Taiwan Normal Univ, Inst Electroopt Sci & Technol, Taipei, Taiwan
关键词
age; immunomagentic reduction assay; plasma tau; biomarker; normal cognition; ALZHEIMERS ASSOCIATION WORKGROUPS; CEREBROSPINAL-FLUID LEVELS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; ELEVATED LEVELS; AMYLOID-BETA; BRAIN-INJURY; IMPAIRMENT; PROTEIN; BIOMARKERS;
D O I
10.3389/fnagi.2017.00051
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Using an ultra-sensitive technique, an immunomagnetic reduction assay, the plasma tau level can be measured to a limit of quantification of pg/ml. In total 126 cognitively normal middle-aged and older adults (45-95 years old) were recruited. The plasma tau levels were significantly higher in the older group (aged 65-95 years) 18.14 +/- 7.33 pg/ml than those in the middle-aged group (aged 45-64 years) 14.35 +/- 6.49 pg/ml when controlled gender and ApoE epsilon 4 carrier status (F = 3.102, P = 0.029). The ApoE epsilon 4 carriers had higher plasma tau levels than the non-carriers when controlled age and gender (F = 6.149, P = 0.001). Men had higher plasma tau levels than their women counterparts when controlled ApoE epsilon 4 carrier status and gender (F = 6.149, P = 0.001). The plasma tau levels were found to be positively associated with their ages (r = 0.359, P < 0.001). Regression analysis showed that age explained approximately 13% of the variance in the plasma tau levels, and explained more than 10% of the variance in the volumes of the hippocampus and white matter hypodensity (R-2 change 0.123 similar to 0.167, all P < 0.001), and explained less than 10% of the variance in the volume of the amygdala, and central part of the corpus callosum (R-2 change 0.085 similar to 0.097, all P = 0.001). However, the plasma tau levels do not further explain any residual variance in the volume of brain structures. In conclusion, the effect of age on the plasma tau levels should always be considered in clinical applications of this surrogate biomarker to middle-aged and elderly subjects.
引用
收藏
页数:6
相关论文
共 36 条
[11]   Core candidate neurochemical and imaging biomarkers of Alzheimer's disease [J].
Hampel, Harald ;
Buerger, Katharina ;
Teipel, Stefan J. ;
Bokde, Arun L. W. ;
Zetterberg, Henrik ;
Blennow, Kaj .
ALZHEIMERS & DEMENTIA, 2008, 4 (01) :38-48
[12]  
Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199
[13]  
Hua M.S., 2005, WECHSLER MEMORY SCAL, V3rd
[14]   ApoE and Aβ in Alzheimer's Disease: Accidental Encounters or Partners? [J].
Kanekiyo, Takahisa ;
Xu, Huaxi ;
Bu, Guojun .
NEURON, 2014, 81 (04) :740-754
[15]   Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease? [J].
Kapaki, E ;
Kilidireas, K ;
Paraskevas, GP ;
Michalopoulou, M ;
Patsouris, E .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (03) :401-403
[16]   Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization [J].
Lewczuk, Piotr ;
Lelental, Natalia ;
Lachmann, Ingolf ;
Holzer, Max ;
Flach, Katharina ;
Brandner, Sebastian ;
Engelborghs, Sebastiaan ;
Teunissen, Charlotte E. ;
Zetterberg, Henrik ;
Luis Molinuevo, Jose ;
Mroczko, Barbara ;
Blennow, Kaj ;
Popp, Julius ;
Parnetti, Lucilla ;
Chiasserini, Davide ;
Perret-Liaudet, Armand ;
Spitzer, Philipp ;
Maler, Juan Manuel ;
Kornhuber, Johannes .
JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (01) :159-170
[17]   Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia [J].
Llorens, Franc ;
Schmitz, Matthias ;
Karch, Andre ;
Cramm, Maria ;
Lange, Peter ;
Gherib, Kerim ;
Varges, Daniela ;
Schmidt, Christian ;
Zerr, Inga ;
Stoeck, Katharina .
ALZHEIMERS & DEMENTIA, 2016, 12 (05) :577-589
[18]   Plasma tau in Alzheimer disease [J].
Mattsson, Niklas ;
Zetterberg, Henrik ;
Janelidze, Shorena ;
Insel, Philip S. ;
Andreasson, Ulf ;
Stomrud, Erik ;
Palmqvist, Sebastian ;
Baker, David ;
Hehir, Cristina A. Tan ;
Jeromin, Andreas ;
Hanlon, David ;
Song, Linan ;
Shaw, Leslie M. ;
Trojanowski, John Q. ;
Weiner, Michael W. ;
Hansson, Oskar ;
Blennow, Kaj .
NEUROLOGY, 2016, 87 (17) :1827-1835
[19]   The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].
McKhann, Guy M. ;
Knopman, David S. ;
Chertkow, Howard ;
Hyman, Bradley T. ;
Jack, Clifford R., Jr. ;
Kawas, Claudia H. ;
Klunk, William E. ;
Koroshetz, Walter J. ;
Manly, Jennifer J. ;
Mayeux, Richard ;
Mohs, Richard C. ;
Morris, John C. ;
Rossor, Martin N. ;
Scheltens, Philip ;
Carrillo, Maria C. ;
Thies, Bill ;
Weintraub, Sandra ;
Phelps, Creighton H. .
ALZHEIMERS & DEMENTIA, 2011, 7 (03) :263-269
[20]   Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis [J].
Mellergard, J. ;
Tisell, A. ;
Blystad, I. ;
Gronqvist, A. ;
Blennow, K. ;
Olsson, B. ;
Dahle, C. ;
Vrethem, M. ;
Lundberg, P. ;
Ernerudh, J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (01) :112-121